GURUFOCUS.COM » STOCK LIST » Basic Materials » Metals & Mining » Crism Therapeutics Corp (LSE:CRTX) » Definitions » Revenue per Share

Crism Therapeutics (LSE:CRTX) Revenue per Share : £-0.00 (TTM As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Crism Therapeutics Revenue per Share?

Crism Therapeutics's revenue per share for the six months ended in Jun. 2024 was £0.00. Crism Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.00.

During the past 12 months, the average Revenue Per Share Growth Rate of Crism Therapeutics was -100.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Crism Therapeutics's Revenue per Share or its related term are showing as below:

LSE:CRTX's 3-Year Revenue Growth Rate is not ranked *
in the Metals & Mining industry.
Industry Median: 9.7
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Crism Therapeutics Revenue per Share Historical Data

The historical data trend for Crism Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crism Therapeutics Revenue per Share Chart

Crism Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Crism Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.94 - -

Competitive Comparison of Crism Therapeutics's Revenue per Share

For the Other Industrial Metals & Mining subindustry, Crism Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crism Therapeutics's PS Ratio Distribution in the Metals & Mining Industry

For the Metals & Mining industry and Basic Materials sector, Crism Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Crism Therapeutics's PS Ratio falls into.



Crism Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Crism Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=0/8.705
=0.00

Crism Therapeutics's Revenue Per Share for the quarter that ended in Jun. 2024 is calculated as

Revenue Per Share (Q: Jun. 2024 )=Revenue (Q: Jun. 2024 )/Shares Outstanding (Diluted Average) (Q: Jun. 2024 )
=0/6.076
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Crism Therapeutics  (LSE:CRTX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Crism Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Crism Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Crism Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.

Crism Therapeutics Headlines

No Headlines